>
Iran's IRGC Warns It Will Expand 'Geography of the War' If the US Attacks Again
This isn't sci-fi, AI is already killing people
Redrawing the Map of the Middle East?
How Human Extinction Became the Default Setting
BEYOND THE MOON: NASA plans a nuclear-powered fleet to push DEEPER into space
Big Oil Backs Mazama's $135 Million Bet On Superhot Geothermal
Quantum compass takes flight on Northrop's Lumberjack drone
Terrifying AI Behavior Even Its Creators Couldn't Explain
WW3 Near-Miss? AI Hallucinated Nuclear Weapons Components Aboard Chinese Vessel Bound For Iran
Stripe Is Building the Toll Road for the Machine Economy
Toyota Dakar hopeful swaps twin-turbo V6 for hydrogen fuel cells
4-min turbo-inflatable cubic camp castle is now available in the USA
Researchers Used Claude To Hack OpenAI Employee Accounts
Chinese Scientists Develop New Oil Refining Method That Cuts Energy Use by 90%

Known as "histotripsy," the method and machinery have already been tested successfully in animals and humans, and has just been approved for use by the FDA.
HistoSonics is a company founded in 2009 to create an ultrasound device that both screens for tumors and administers histotripsy. It was born from the efforts of scientists at the University of Michigan who co-founded the firm.
"Histotripsy is an exciting new technology that, although it is in early stages of clinical use, may provide a noninvasive treatment option for patients with liver cancer. Hopefully it can be combined with systemic therapies for a synergistic therapeutic effect," said Mishal Mendiratta-Lala, professor of radiology with Michigan Medicine.
Mendiratta-Lala was the principal investigator of an FDA human trial started in 2021 which confirmed that HistoSonic's device, called Edison, can destroy cancer tumors.